Guardant Reveal aids organ preservation in rectal cancer treatment

PALO ALTO, Calif. - Guardant Health , Inc. (NASDAQ: NASDAQ:GH), a precision oncology company with a market capitalization of $5.8 billion, has presented new data at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI) demonstrating the utility of its Guardant Reveal™ test in rectal cancer treatment. The phase II NEO trial data, featured on January 25, 2025, shows that the liquid biopsy tool can aid in decision-making for organ preservation in patients with node-negative rectal cancer undergoing neoadjuvant chemotherapy. According to InvestingPro data, the company has demonstrated strong revenue growth of 29.2% over the last twelve months.

According to the findings, tumor-free circulating tumor DNA (ctDNA) detection using Guardant Reveal™ serves as a reliable tool to support organ-preserving strategies in these patients. The data suggests that the test could help identify patients who may avoid more invasive surgeries without compromising treatment efficacy.

Guardant Health's Chief Medical (TASE:PMCN) Officer, Dr. Craig Eagle, underscored the growing evidence supporting precision oncology tools like liquid biopsy in detecting gastrointestinal (GI) cancers, informing treatment selection, and monitoring for recurrence and therapy response. "Findings presented at ASCO GI demonstrate the advancements being made by Guardant Health and our partners in these areas and show the potential for these tools to provide even more personalized cancer care, leading to better patient outcomes," said Dr. Eagle.

The company's presence at the symposium included additional co-authored abstracts and presentations that spanned a range of topics, including the impact of mutations on treatment response in colorectal and biliary tract cancers, and the benefits of blood-based screening for colorectal, gastric, and esophageal cancers.

Guardant Health's research and development in precision oncology aim to provide critical insights into disease drivers through advanced blood and tissue tests, real-world data, and AI analytics. These tests are designed to improve outcomes across all stages of care, from early cancer screening and monitoring for recurrence to treatment selection for advanced cancer patients.

This recent presentation at ASCO GI 2025 is part of the company's ongoing efforts to advance the field of precision oncology and provide tools for more individualized treatment approaches. For investors seeking deeper insights, InvestingPro offers comprehensive analysis with 12 additional ProTips and a detailed Pro Research Report, providing valuable context for evaluating Guardant Health's market position and growth potential. The information is based on a press release statement, and the full abstracts from Guardant Health can be found on the ASCO website.

In other recent news, Guardant Health has been the focus of multiple analyst ratings and significant developments. Raymond (NSE:RYMD) James and TD Cowen have maintained their positive outlook on Guardant Health, holding firm with their respective price targets of $39 and $42. BTIG has raised its price target to $55, while Canaccord Genuity reaffirmed its $42 target. This follows the recent announcement of expanded Medicare coverage for Guardant Health's Reveal test, which is designed to detect colon cancer recurrence.

Analysts from these firms anticipate that this development will significantly contribute to Guardant Health's growth, with expectations for a growth rate exceeding 20%. They also highlight the company's strong revenue growth of 29.2% in the last twelve months. Guardant Health's partnership with pharmaceutical company Boehringer Ingelheim to seek regulatory approval for Guardant360® CDx, a liquid biopsy test, is also noted as a key development.

Raymond James and TD Cowen's positive stance is further reinforced by the company's strong financial position, with a current ratio of 6.22, indicating strong liquidity. Investors are looking forward to Guardant Health's fourth-quarter results for further insights into its financial health and operational progress.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.